Effects of VerifyNow P2Y12 test on clinical outcomes of patients with coronary revascularization: A meta-analysis

AIM To investigate the effects of VerifyNow P2Y12 test on the clinical outcomes of patients taking clopidogrel undergoing coronary revascularization. METHODS We searched the Cochrane Library (2014 Section 3), Pubmed, EMbase, Highwire, CBM, CNKI and other biomedical databases and collected data as of March 2014 of VerifyNow P2Y12 test in patients with coronary revascularization, follow-up time of 6-12 months, randomized controlled trials and cohort studies. After extracting valid data, a meta-analysis was conducted using STATA 12.0 software. RESULTS The meta-analysis included 14 studies with a total of 17 643 patients. The results showed that the detection rate of VerifyNow P2Y12 test was high in all-cause mortality (RR=1.572, 95%CI 1.220, 2.025, P=0.000), incidence of myocardial infarction (RR=1.981, 95%CI 1.443, 2.720, P=0.000), stent thrombosis rate (RR=2.205, 95%CI 1.643, 2.960, P=0.000) and incidence of stroke (RR=2.288, 95%CI 1.195, 4.380, P=0.0129). For target vessel revascularization, two sets of results showed no significant difference (RR=1.148, 95%CI 0.809, 1.629, P=0.439). CONCLUSION VerifyNow P2Y12 platelet reactivity detection has predictive value for all-cause death, myocardial infarction, stent thrombosis, stroke and other cardiovascular events in patients taking clopidogrel.